ClinicalTrials.gg
Enrolling by invitationNCT06958640Updated May 6, 2025

Da Qing Offspring Study

An observational study in Diabetes Mellitus, Cardiovascular Diseases (CVD) and Offspring, Adult, sponsored by China-Japan Friendship Hospital. Enrolling by invitation at 1 site in China. Per ClinicalTrials.gov, last updated 2025-05-06.

Primary conditionPrediabetic StateRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prediabetic State
Why
  1. The study's listed conditions name Prediabetic State, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by China-Japan Friendship Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Started
2025
with 9 others
Observational
7 of 51
5 open now
Primary completion
2026-12
later than 8 of 24 live
Registered
39th of 51
by date
Lead sponsor
2 of 51
China-Japan Friendship Hospital

Among the 51 studies in Prediabetic State with a site in China, this one is one of 10 that started in 2025, is one of 7 observational ones, reaches primary completion later than 8 of the 24 other live ones, and was the 39th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

This is an observational study tracking families and offspring of three cohorts from the 1986 Da Qing study: newly diagnosed diabetes, impaired glucose tolerance, and normoglycemia groups. Based on the original participants, the study will further include their spouses, first to third-generation offspring, and spouses of the offspring. General demographic information will be collected, and anthropometric measurements will be refined. A structured questionnaire will be used to gather disease history, family history of diabetes, and related information. Comprehensive diabetes-related laboratory screening and complication assessments will be conducted. A standardized biobank will be established, including blood and urine samples from the Da Qing Offspring Study, to support future research on epigenetics, metabolomics, and other mechanisms.

03

Conditions studied

  • Diabetes Mellitus
  • Cardiovascular Diseases (CVD)
  • Offspring, Adult
  • Impaired Glucose Tolerance (Prediabetes)
  • Prevention
  • Cancer
  • Comorbidity
  • Inter- and Transgenerational Inheritance
04

In context

Prediabetic State Reclassified

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

This study's planned enrollment of 5,000 is above the median of 224 across 129 observational studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.

Compared within Prediabetic State, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Original subjects and spouses (70-90 years old), N=576+576=1152; First generation (50-70 years old), based on an average of 3 children per family, N=576*3=1728; The marriage rate of first generation is 90%, and the spouses N=1555; Second generation (25-45 years old), based on 90% of families having children, with an average of 1 child per family, N=1555*90%*1=1400; The marriage rate of second generation is 70%, and the spouses N=1400*70%=980; Third generation (1-20 years old), based on 80% of families having children, with an average of 1 child per family, N=980*80%*1=784; Based on the follow-up rate of 70%, the total number of people is about 5,000.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spouses of the original Daqing diabetes Prevention Research Population (IGT), offspring 1 to 3 generations, and offspring spouses were included in the study, without special restrictions on subjects' gender, age, basic disease status, etc。
  • Conduct a death agent investigation for some deceased members.

Exclusion criteria

Exclusion Criteria:

▪People who are unwilling to participate in this study

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lifestyle intervention subjects and offspring group

    The subjects who received lifestyle intervention in the original Daqing Diabetes Prevention Study, their spouses, children 1 to 3, and spouses of their offspring were included in the study.

    Behavioral: Lifestyle interventions

  • Control group subjects and offspring

    The subjects who did not received lifestyle intervention in the original Daqing Diabetes Prevention Study, their spouses, children 1 to 3, and spouses of their offspring were included in the study.

Interventions

  • BehavioralLifestyle interventions

    Dietary intervention: 30kcal energy intake per kilogram of body weight per day, increase vegetable intake, control sugar and alcohol intake, encourage overweight and obese people to lose weight, lose 0.5-1kg per month until the weight reaches the target. Exercise intervention: Appropriate physical activity in spare time, 30-40 minutes per day, 5 times a week.

07

What researchers measure

Primary outcomes

  1. Cumulative incidence rate of diabetes

    This study statistically analyzed the cumulative incidence rate of diabetes at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

Secondary outcomes

  1. weight

    The subject's weight is recorded and the results are reported in kilograms.

    Time frame: Through study completion, an average of about 1.5 years

  2. waist circumference

    The subjects' waist circumference was recorded and the waist circumference results were reported in centimeters.

    Time frame: Through study completion, an average of about 1.5 years

  3. Height

    The subject's height was recorded, and the results were recorded in centimeters.

    Time frame: Through study completion, an average of about 1.5 years

  4. Exercise frequency and intensity

    The subjects' daily exercise frequency and intensity were recorded.

    Time frame: Through study completion, an average of about 1.5 years

  5. Coronary heart disease incidence

    This study statistically analyzed the incidence of coronary heart disease at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  6. all-cause deaths

    This study counted all-cause deaths at the end of the study through death certificate, medical record review, family interview

    Time frame: Through study completion, an average of about 1.5 years

  7. incidence of diabetic peripheral neuropathy

    This study statistically analyzed the incidence of diabetic peripheral neuropathy at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  8. other cause mortality

    This study statistically analyzed other cause mortality at the end of the study through death record, medical record review, family interview

    Time frame: Through study completion, an average of about 1.5 years

  9. cardiovascular mortality rate

    This study statistically analyzed the cardiovascular mortality rate at the end of the study through death certificate, medical record review, family interview

    Time frame: Through study completion, an average of about 1.5 years

  10. incidence of blindness

    This study statistically analyzed the incidence of blindness at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  11. Diabetic retinopathy incidence

    This study statistically analyzed the incidence of diabetic retinopathy at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  12. Diabetic nephropathy incidence

    This study statistically analyzed the incidence of diabetic nephropathy at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  13. Peripheral vascular disease incidence

    This study statistically analyzed the incidence of peripheral vascular disease at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  14. Heart failure incidence

    This study statistically analyzed the incidence of heart failure at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  15. Stroke incidence

    This study statistically analyzed the incidence of stroke at the end of the study through interview, medical record review, physical examination

    Time frame: Through study completion, an average of about 1.5 years

  16. dietary habits

    The subjects' eating habits and dietary preferences were assessed through patient interviews.

    Time frame: Through study completion, an average of about 1.5 years

  17. health-related quality of life

    The EuroQol questionnaire or health status questionnaire was administered through patient interviews to assess the subjects' health-related quality of life.

    Time frame: Through study completion, an average of about 1.5 years

  18. blood pressure

    During the visit, the subjects' systolic and diastolic blood pressures were measured at rest by physical examination. The measurements were performed twice and the average was taken.

    Time frame: Through study completion, an average of about 1.5 years

  19. blood sugar

    Blood samples were collected from the subjects at 1 hour and 2 hours after the steamed bread meal when they were fasting. The blood samples were used to test blood sugar levels and blood lipids, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.

    Time frame: Through study completion, an average of about 1.5 years

  20. blood lipid

    Venous blood was collected from the subjects in a fasting state. The blood samples were used to test blood lipid status, including total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.

    Time frame: Through study completion, an average of about 1.5 years

  21. skin AGE

    The skin AGE of the subjects was measured by physical examination. After cleaning the inner skin of the forearm, the AGE Reader probe was gently placed on the skin surface, the excitation light was emitted and the fluorescence intensity was recorded. The results were repeated 3 times and the average value was taken.

    Time frame: Through study completion, an average of about 1.5 years

  22. Tidal Volume

    The subjects were assessed for Tidal Volume, which reflects the ventilation efficiency in the basic breathing state. Tidal Volume is measured in liters.

    Time frame: Through study completion, an average of about 1.5 years

  23. Functional Residual Capacity

    Subjects were assessed for Functional Residual Capacity, which reflects lung capacity. Functional Residual Capacity is measured in liters.

    Time frame: Through study completion, an average of about 1.5 years

  24. Forced Vital Capacity

    The subjects were assessed for Forced Vital Capacity, which reflects the overall ventilation capacity of the lungs. Forced Vital Capacity is measured in liters.

    Time frame: Through study completion, an average of about 1.5 years

  25. Forced Expiratory Volume in 1 second

    The subjects were assessed for Forced Expiratory Volume in 1 second, which reflects respiratory reserve capacity. Forced Expiratory Volume in 1 second is measured in liters.

    Time frame: Through study completion, an average of about 1.5 years

08

Study locations

1 site
09

References and documents

Publications

  • Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K, Hamalainen H, Harkonen P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006 Nov 11;368(9548):1673-9. doi: 10.1016/S0140-6736(06)69701-8. PubMed 17098085 ↗
  • Sakane N, Sato J, Tsushita K, Tsujii S, Kotani K, Tsuzaki K, Tominaga M, Kawazu S, Sato Y, Usui T, Kamae I, Yoshida T, Kiyohara Y, Sato S, Kuzuya H; Japan Diabetes Prevention Program (JDPP) Research Group. Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance. BMC Public Health. 2011 Jan 17;11(1):40. doi: 10.1186/1471-2458-11-40. PubMed 21235825 ↗
  • Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50. doi: 10.1056/NEJM200105033441801. PubMed 11333990 ↗
  • Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006 Feb;49(2):289-97. doi: 10.1007/s00125-005-0097-z. Epub 2006 Jan 4. PubMed 16391903 ↗
  • Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44. doi: 10.2337/diacare.20.4.537. PubMed 9096977 ↗
  • Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512. PubMed 11832527 ↗
  • Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, Zhang B, Feng X, Li H, Chen X, Cheng YJ, Gregg EW, Hu Y, Bennett PH, Li G; Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019 Jun;7(6):452-461. doi: 10.1016/S2213-8587(19)30093-2. Epub 2019 Apr 26. PubMed 31036503 ↗
  • Gong Q, Zhang P, Wang J, Gregg EW, Cheng YJ, Li G, Bennett PH; Da Qing Diabetes Prevention Outcome Study Group. Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: A post hoc analysis of Da Qing Diabetes Prevention Outcome Study. Diabetes Obes Metab. 2021 Oct;23(10):2385-2394. doi: 10.1111/dom.14481. Epub 2021 Jul 27. PubMed 34212465 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 6, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06958640
Collaborators
Daqing Oil Field Hospital
Responsible party
Bo Zhang (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
May 6, 2025
Start date
Apr 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2025

Study contacts

Liping Yu, Doctor
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion